SWP
ARQT icon

Stratos Wealth Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Stratos Wealth Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Sell
10,251
-5,570
-35% -$130K ﹤0.01% 1476
2026
Q1 		$373K Buy
+15,821
New +$404K ﹤0.01% 1205

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Stratos Wealth Partners's ARQT Position: Q2 2026 in Review

Stratos Wealth Partners reduced its Arcutis Biotherapeutics (ARQT) stake by 35% in Q2 2026, selling an estimated $130K and leaving 10,251 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #1476.

Stratos Wealth Partners first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. The position peaked at $373K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Stratos Wealth Partners held 10,251 shares of Arcutis Biotherapeutics worth $269K as of Q2 2026.
  • Stratos Wealth Partners sold 5,570 Arcutis Biotherapeutics shares in Q2 2026, an estimated $130K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1476 holding.
  • Stratos Wealth Partners first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • Stratos Wealth Partners's Arcutis Biotherapeutics position peaked at $373K in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.